Anti-HER-2 engineering antibody ChA21 inhibits growth and induces apoptosis of SK-OV-3 cells
详细信息 查看全文
- 作者：AnLi Zhang (1)
Hua Xue (1)
XiaoGuang Ling (1)
Yi Gao (1)
Feng Yang (1)
LianSheng Cheng (2)
Jing Liu (2)
Qiang Wu (1) - 刊名：Journal of Experimental & Clinical Cancer Research
- 出版年：2010
- 出版时间：December 2010
- 年：2010
- 卷：29
- 期：1
- 全文大小：4978KB
- 参考文献：1. Jemal A, Siegel R, Ward E, / et al.: Cancer statistics. / Cancer Journal for Clinicians 2008, 58:71鈥?6. CrossRef
2. Breedlove G, Busenhart C: Screening and detection of ovarian cancer. / Journal of Midwifery & Women's Health 2005, 50:51鈥?4. CrossRef
3. Bast RC, Hennessy B, Mills GB: The biology of ovarian cancer: new opportunities for translation. / Nature Reviews Cancer 2009, 9:415鈥?28. CrossRef
4. Carpenter G: Receptors for epidermal growth factor and other polypeptide mitogens. / Annu Rev Biochem 1987, 56:881鈥?14. CrossRef
5. Coussens L, Yang-Feng TL, Liao YC, / et al.: Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. / Science 1985, 230:1132鈥?139. CrossRef
6. Popescu NC, King CR, Kraus MH: Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12鈥?1.32. / Genomics 1989, 4:362鈥?66. CrossRef
7. Yarden Y, Sliwkowski MX: Untangling the ErbB signalling network. / Nat Rev Mol Cell Biol 2001, 2:127鈥?37. CrossRef
8. Slamon DJ, Godolphin W, Jones LA: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. / Science 1989, 244:707鈥?12. CrossRef
9. Verri E, Guglielmini P, Puntoni M: HER2/neu oncoprotein overexpression in epithelial ovarian cancer: evaluation of its prevalence and prognostic significance. / Oncology 2005, 68:154鈥?61. CrossRef
10. Cheng JD, Rieger PT, von Mehren M: Recent advances in immunotherapy and monoclonal antibody treatment of cancer. / Semin Oncol Nurs 2000, 16:2鈥?2. CrossRef
11. Bell Richard: What Can We Learn from Herceptin Trials in Metastatic Breast Cancer? / Oncology 2002, 63:39鈥?6. CrossRef
12. Cuello Mauricio, Seth A, Ettenberg , Amy S, / et al.: Down-Regulation of the erbB-2 Receptor by Trastuzumab (Herceptin) Enhances Tumor Necrosis Factor-related Apoptosis-inducing Ligand-mediated Apoptosis in Breast and Ovarian Cancer Cell Lines that Overexpress erbB-2. / Cancer Res 2001, 61:4892鈥?00.
13. Cho HS, Mason K, Ramyar KX, / et al.: Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. / Nature 2003, 421:756鈥?60. CrossRef
14. Fujimura M, Katsumata N, Tsuda H, / et al.: HER2 Is Frequently Over-expressed in Ovarian Clear Cell Adenocarcinoma: Possible Novel Treatment Modality Using Recombinant Monoclonal Antibody against HER2, Trastuzumab. / Jpn J Cancer Res 2002, 93:1250鈥?257.
15. Dean-Colomb W, Esteva FJ: Her2-positive breast cancer: herceptin and beyond. / Eur J Cancer 2008, 44:2806鈥?812. CrossRef
16. Cheng LS, Liu AP, Yang JH: Construction, expression and characterization of the engineered antibody against tumor surface antigen, p185(c-erbB-2). / Cell Res 2003, 13:35鈥?8. CrossRef
17. Wang Jing, Shi Yu, Liu Yanqi: Purification and characterization of a single-chain chimeric anti-p185 antibody expressed by CHO-GS system. / Protein expression and purification 2005, 41:68鈥?6. CrossRef
18. Hu S, Zhu Z, Li L, / et al.: Epitope mapping and structural analysis of an anti-ErbB2 antibody A21: Molecular basis for tumor inhibitory mechanism. / Proteins 2008, 70:938鈥?49. CrossRef
19. Wang C, Li Y, Li P: Generation and Characterization of monoclonal antibodies specific for the oncogene product P185 neu/c-erbB-2 by surface epitope masking (SEM). / J Chin Immunol 2000, 16:539鈥?41.
20. Ping LI, Yun LI, Chen Wang: Investigation on the anti-cancer activities of anti-p185 monoclonal antibodies in vitro. / Chin Immunol 2002, 18:33鈥?5.
21. Steffen AC, G枚string L, Tolmachev V, / et al.: Differences in radiosensitivity between three HER2 overexpressing cell lines. / Eur J Nucl Med Mol I 2008, 35:1179鈥?191. CrossRef
22. Sujun L, Xun L, Daxu L, / et al.: Tumor inhibition and improved immunity in mice treated with flavone from Cirsium japonicum DC. / International Immunopharmacology 2006, 6:1387鈥?393. CrossRef
23. Jackson JG, St Clair P, Sliwkowski MX, / et al.: Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects. / Cancer Res 2004, 64:2601鈥?609. CrossRef
24. Vogel CL, Cobleigh MA, Tripathy D, / et al.: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. / J Clin Oncol 2002, 18:719鈥?26. CrossRef
25. Perez EA: Cardiac toxicity of ErbB2-targeted therapies: what do we know? / Clin Breast Cancer 2008, 8:114鈥?20. CrossRef
26. Hattori K, Nishi Y, Nakamura S: Evaluation of cardiac dysfunction after herceptin treatment in patients with metastatic breast cancer by echocardiography. / Rinsho Byori 2007, 55:120鈥?25.
27. Vahid B, Marik PE: Pulmonary complications of novel antineoplastic agents for solid tumors. / Chest 2008, 133:528鈥?38. CrossRef
28. Slamon DJ, Leyland-Jones B, / et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. / N Engl J Med 2001, 344:783鈥?92. CrossRef
29. Calabrich A, Fernandes Gdos S, Katz A: Trastuzumab: mechanisms of resistance and therapeutic opportunities. / Oncology (Williston Park) 2008, 22:1250鈥?258.
30. Chen MH: Cardiac dysfunction induced by novel targeted anticancer therapy: an emerging issue. / Curr Cardiol Rep 2009, 11:167鈥?74. CrossRef
31. Wang JN, Feng JN, Yua M: Structural analysis of the epitopes on erbB2 interacted with inhibitory or non-inhibitor monoclonal antibodies. / Mol Immu nol 2004, 40:963鈥?69. CrossRef
32. Tortora G, di Isernia G, Sandomenico C, / et al.: Synergistic inhibition of growth and induction of apoptosis by 8-chloro-cAMP and paclitaxel or cisplatin in human cancer cells. / Cancer Res 1997, 57:5107鈥?111.
33. Cummings MC, Winterford CM, Walker NL: Apoptosis. / Am J Surg Pathol 1997, 21:88鈥?01. CrossRef
34. Gillardon F, Wickert H, Zimmermann M: Up-regulation of bax and down-regulation of bcl-2 is associated with kainate-induced apoptosis in mouse brain. / Neurosci Lett 1995, 192:85鈥?8. CrossRef
35. Adams JM, Cory S: The bcl-2 protein family: arbiters of cell surival. / Science 1998, 281:1322鈥?326. CrossRef
36. Rakesh K, Mahitosh M, Allan L, / et al.: Overexpression of HER2 Modulates Bcl-2, Bcl-XL, and Tamoxifen-induced Apoptosis in Human MCF-7 Breast Cancer Cells. / Clin Cancer Res 1996, 2:1215鈥?219.
37. Zheng L, Weiya X, BingLiang F, / et al.: Targeting HER-2/neu-overexpressing breast cancer cells by an antisense iron responsive element-directed gene expression. / Cancer lett 2001, 174:151鈥?58. CrossRef - 作者单位：AnLi Zhang (1)
Hua Xue (1)
XiaoGuang Ling (1)
Yi Gao (1)
Feng Yang (1)
LianSheng Cheng (2)
Jing Liu (2)
Qiang Wu (1)
1. Department of Pathology, Anhui Medical University, 69# Meishan Road, Hefei, Anhui, 230032, PR China
2. School of Life Science, University of Science and Technology of China, Hefei, 230027, PR China - ISSN：1756-9966
文摘
Background and Aims Anti-HER-2 antibodies targeting distinct epitopes have different biological functions on cancer cells. In a previous study, we demonstrated that anti-HER-2 engineering antibody ChA21 was able to bind to subdomain I of HER-2 extracellular domain. In this study, The effects of ChA21 on growth and apoptosis against ovarian carcinoma cell SK-OV-3 over-expressing HER-2 in vitro and in vivo were investigated. Methods Cell growth inhibition was evaluated by MTT assay. Apoptosis was detected by TUNEL stain, transmission electron microscopy and flow cytometry on cultured cells and tissue sections from nude mice xenografts. The apoptosis-related proteins Bax and Bcl-2 were assessed by immunohistochemistry. Results We found that treatment of ChA21 caused a dose-dependent decrease of cell proliferation in vitro and a significant inhibition of tumor growth in vivo. ChA21 therapy led to a significant increase in the induction of apoptosis, and up-regulated the expression of Bax, while the expression of Bcl-2 was down-regulated. Conclusion These data suggest that ChA21 inhibits the growth and induces apoptosis of SK-OV-3 via regulating the balance between Bax and Bcl-2.